Clinical trials / NCT02859961
NCT02859961Phase 2, phase 3Completed

Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection

Study sponsor: CytoDyn, Inc.

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2020-09-16Actual
Enrollment · participants562Actual
Source updated2026-03-04Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Proportion of participants who remain on PRO 140 monotherapy regimen at the end of week 48 without experiencing virologic failure

+ After

Measure: Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic Failure

Actual enrollment increased by 6 participants

− Before

556 participants (actual)

+ After

562 participants (actual)

Check registry source